SCHEMBL15620249

SCHEMBL15620249

COc1ccc(CN2C(=O)Cc3ccccc3-c3cccc(F)c32)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
CASP3 P42574 2/20 0.69
APAF1 O14727 2/20 0.69
GAA P10253 1/20 0.69
SENP8 Q96LD8 1/20 0.69
SENP7 Q9BQF6 1/20 0.69
SENP6 Q9GZR1 1/20 0.69
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
HPGD P15428 1/20 0.48
CHRM5 P08912 3/20 0.47
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
BLM P54132 1/20 0.46
CMA1 P23946 1/20 0.45
CASP6 P55212 1/20 0.45
HTT P42858 1/20 0.44
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15627434 0.87 MEN1 (0.70) MEN1KMT2ACASP3APAF1GAA
SCHEMBL3851940 0.82 MEN1 (0.77) MEN1KMT2ACASP3APAF1GAA
SCHEMBL2580937 0.82 KMT2A (1.00) MEN1KMT2ACASP3APAF1GAA
SCHEMBL31259596 0.81 CHRM5 (0.49) MEN1KMT2ACASP3APAF1GAA
SCHEMBL31430163 0.81 MEN1 (0.51) MEN1KMT2ACASP3APAF1GAA
SCHEMBL31259672 0.80 MEN1 (0.48) MEN1KMT2ACASP3APAF1GAA
SCHEMBL31259599 0.79 KDM4E (0.60) MEN1KMT2ACASP3APAF1GAA
SCHEMBL31259624 0.79 KDM4E (0.49) MEN1KMT2ACASP3APAF1GAA
SCHEMBL14938439 0.76 MEN1 (0.71) MEN1KMT2ACASP3APAF1GAA
SCHEMBL15627197 0.76 KDM4E (0.48) MEN1KMT2ACASP3APAF1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2897938-B1 FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-03-15 EP disclosed
EP-2897938-B1 FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-03-15 EP disclosed
US-9133126-B2 Fluoroalkyl dibenzoazepinone compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-09-15 US disclosed
US-9133126-B2 Fluoroalkyl dibenzoazepinone compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-09-15 US disclosed
US-20150218104-A1 FLUOROALKYL DIBENZOAZEPINONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2015-08-06 US disclosed
US-20150218104-A1 FLUOROALKYL DIBENZOAZEPINONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2015-08-06 US disclosed
EP-2897938-A1 FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS Bristol-Myers Squibb Company (US) 2015-07-29 EP disclosed
WO-2014047370-A1 FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-27 WO disclosed
WO-2014047370-A1 FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218104-A1 FLUOROALKYL DIBENZOAZEPINONE COMPOUNDS DNER, NOTCH3, BCR MEN1 2575/4885KMT2A 1205/4885CASP3 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.